AstraZeneca announces 'robust' results from anti-Covid drug trial
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Monday
August 15, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
MONDAY, AUGUST 15, 2022
AstraZeneca announces 'robust' results from anti-Covid drug trial

Coronavirus chronicle

BSS/AFP
19 November, 2021, 11:25 am
Last modified: 19 November, 2021, 11:29 am

Related News

  • From December no Covid-19 vaccine, except a booster dose, will be given
  • S Korea approves first domestically developed Covid vaccine
  • S Korea plans to provide Covid vaccine to North
  • WTO meeting on Covid vaccine rights waiver went 'very well' -chair
  • Denmark becomes first country to suspend Covid vaccinations

AstraZeneca announces 'robust' results from anti-Covid drug trial

A six-month follow-up trial "showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination", it said in a statement.

BSS/AFP
19 November, 2021, 11:25 am
Last modified: 19 November, 2021, 11:29 am
Photo/courtesy
Photo/courtesy

Pharmaceutical giant AstraZeneca on Thursday announced that clinical trials of an antibody-based Covid-19 drug had shown robust efficacy and long-term prevention.

The Anglo-Swedish laboratory follows in the footsteps of US firms Merck and Pfizer, which announced in October and early November respectively that they had developed drugs that could prevent severe forms of the disease, and that could be taken at the first sign of symptoms.

The AstraZeneca drug AZD7442, made from a combination of two antibodies, has been undergoing final stage clinical trials to assess its safety and efficacy.

A six-month follow-up trial "showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination", it said in a statement.

One 300mg IM dose reduced the risk of developing symptomatic COVID-19 compared to placebo by 83 percent, it added.

More than 75 percent of participants had co-morbidities that put them at high risk for severe COVID-19 if they were to become infected, but no severe cases were recorded.

Another trial to test its efficacy in treating those already suffering from "mild to moderate" Covid symptoms showed that one 600mg IM dose reduced the risk of developing severe illness or death by 88 percent.

"These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives," said Hugh Montgomery, professor of intensive care medicine at University College London.

"Importantly, six months of protection was maintained despite the surge of the Delta variant among these high-risk participants who may not respond adequately to vaccination."

AstraZeneca said the full results of both trials would be submitted for publication to a peer-reviewed medical journal.

It has already submitted an application to US regulators for approval of the drug to treat Covid-19.

AstraZeneca's separate Covid vaccine, developed with the University of Oxford, helped enable Britain's speedy Covid vaccination drive after it was approved in December 2020.

Top News / World+Biz / Health

AstraZeneca / Covid -19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh may get annual fixed quota for food imports from India
    Bangladesh may get annual fixed quota for food imports from India
  • Illustration: TBS
    His presence felt everywhere
  • Photo: TBS
    Chawkbazar plastic factory fire bought under control

MOST VIEWED

  • Southern hemisphere to get first mRNA vaccine facility
    Southern hemisphere to get first mRNA vaccine facility
  • North Korea's leader Kim Jong Un greets health workers and scientists struggling with the coronavirus disease (Covid-19) pandemic during a photo session in Pyongyang, North Korea, in this undated photo released on August 10, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • A motorist passes by a mural of frontline workers against coronavirus at RK Puram in New Delhi on July 25. Delhi’s Covid-19 recoveries have outstripped new cases on almost all days this month barring a few exceptions, after ramped-up containment and testing efforts over the past month or so. (Sanchit Khanna / HT Photo)
    Delhi to enforce mask mandate again after spurt in Covid cases
  • A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell
    US CDC no longer recommends students quarantine for Covid-19 exposure
  • In this file photo taken on March 2, 2019, Kim Yo Jong, sister of North Korea's leader Kim Jong Un, attends a wreath-laying ceremony at Ho Chi Minh Mausoleum in Hanoi. Photo: Hindustan Times
    Kim Jong Un's sister warns Seoul of 'retaliation' over Covid
  • North Korean leader Kim Jong Un speaks at a politburo meeting of the Worker's Party on the country's coronavirus disease (COVID-19) outbreak response in this undated photo released by North Korea's Korean Central News Agency (KCNA) on May 21, 2022. KCNA via REUTERS
    North Korea declares victory over Covid, suggests leader Kim had it

Related News

  • From December no Covid-19 vaccine, except a booster dose, will be given
  • S Korea approves first domestically developed Covid vaccine
  • S Korea plans to provide Covid vaccine to North
  • WTO meeting on Covid vaccine rights waiver went 'very well' -chair
  • Denmark becomes first country to suspend Covid vaccinations

Features

The macabre multicide: How we failed our supreme leader

The macabre multicide: How we failed our supreme leader

2h | Supplement
Bangabandhu Sheikh Mujibur Rahman with his eldest daughter Sheikh Hasina and his grandson Sajeeb Wazed at his Dhanmondi residence. Photo: Achieve

The darkest night of 15 August

4h | Supplement
As long as the Padma and the Meghna will flow…

As long as the Padma and the Meghna will flow…

5h | Supplement
Baah: A sustainable way to upgrade your home

Baah: A sustainable way to upgrade your home

5h | Brands

More Videos from TBS

Forest Department takes initiative to protect wildlife in Purbachal

Forest Department takes initiative to protect wildlife in Purbachal

4h | Videos
Bangabandhu's humane values

Bangabandhu's humane values

5h | Videos
Why trolling happens on personal matter

Why trolling happens on personal matter

4h | Videos
House that reveals story of Bangladesh

House that reveals story of Bangladesh

5h | Videos

Most Read

1
Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 
Banking

Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 

2
From left Afzal Karim, Murshedul Kabir and Mohammad Jahangir
Banking

Sonali, Agrani and Rupali banks get new MDs

3
Photo: Collected
Transport

Will Tokyo’s traffic model solve Dhaka’s gridlocks?

4
Representational Image. Photo: Collected
Bangladesh

Air passengers should plan extra commute time to airport: DMP

5
Arrest warrant against Habib Group chairman, 4 others 
Crime

Arrest warrant against Habib Group chairman, 4 others 

6
Ambassador of Switzerland to Bangladesh Nathalie Chuard. Photo: Courtesy
Bangladesh

Bangladesh never asked for particular info from Swiss bank: Ambassador

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net